Sat, Dec 27, 2014, 3:23 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • hbomb57108 hbomb57108 Feb 6, 2013 9:47 PM Flag

    Sunitinib-Induced Hemoglobin Changes Are Related to the Dosing Schedule

    Best response combination of 6 and 12 week scans from both 40 mg cohorts were miscalculated from my last post.

    Should read this way

    16/24 PR's= 66.7%
    3/24 CR's= 12.5%

    Total best bone scan response of 24 evaluable 19/24= 79.2%

    If you take pure 12 week scans by evaluable it would look like this combining both 40 mg cohorts

    combination of 2- 40 mg cohorts

    12/20 PR's= 60%
    3/20 CR's= 15%

    Total bone scan response of 20 evaluable patients at 12 weeks= 75%

    From this abstract

    Abstract 4566: Investigator-Sponsored Trial of Efficacy and Tolerability of Cabozantinib at Lower Dose: A Dose- Finding Study in Men with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastases

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You have to read the abstract carefully. There was one cohort of 12 patients reported on for both the 6 and 12 week observation. If you take the best response, there were 10/12 BSR's, 3 of which were CR's. But you should also roll in the 40mg results that DeBono reported in September at ESMO on a sample size of 51 with a 49% BSR (25/51). So if you pool the 40mg data we have 35/63 for a 56% BSR.

      • 1 Reply to erniewerner
      • "There was one cohort of 12 patients reported on for both the 6 and 12 week observation. "

        The abstract I'm looking at clearly shows original 11 patient evaluable bone scan on 1st 40 mg cohort and 13 evaluable on extension cohort on 40 mg dose on UMass abstract. Unless of course the abstract has a typo. Numbers vary depending on whether 6 or 12 week bone scan criteria is used. The 60 mg UMass was never reported to my knowledge. You may think I'm confusing the other cohort for 20 mg, but that is not the case. Actually 3 cohorts in total. 1-20mg and 2-40 mg.

        Regardless, I am glad you posted the NRE extension cohort, this certainly demonstrates the COMET populations more closely. I prefer to use the NRE cohort for my expectations. You wouldn't happen to know if there is public data out there on 60 mg would you?

    • "Total bone scan response of 20 evaluable patients at 12 weeks= 75%"

      That's pretty hat's good isn't it?

      Sentiment: Strong Buy

 
EXEL
1.33+0.04(+3.10%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Prothena Corporation plc
NASDAQFri, Dec 26, 2014 4:00 PM EST
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST